Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis

Bryan Q. Abadie, Paul C. Cremer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Although most patients with acute pericarditis will recover, a minority will have recurrent, debilitating episodes. In these patients, refractory symptoms result in high morbidity, and typically require a prolonged duration of anti-inflammatory treatment. Initially, the efficacy of colchicine in both recurrent pericarditis and periodic fever syndromes suggested the central role of the inflammasome in pericarditis. Subsequently, the success of interleukin-1 antagonists in autoinflammatory diseases prompted further investigation in recurrent pericarditis. In current clinical practice, interleukin-1 antagonists include canakinumab, anakinra, and rilonacept. Both anakinra and rilonacept have demonstrated efficacy in randomized trials of patients with recurrent pericarditis. The aim of the current review is to explain the biological rationale for interleukin-1 antagonists in recurrent pericarditis, highlight supporting clinical evidence, and emphasizing future areas of investigation.

Original languageEnglish (US)
Pages (from-to)459-472
Number of pages14
Issue number4
StatePublished - Jul 2022

ASJC Scopus subject areas

  • Biotechnology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis'. Together they form a unique fingerprint.

Cite this